Skip to content

Study · Non-randomized trial · n = 73 · 2008

2 results

[The therapeutic potential of cerebrolysin in the preventive therapy of Alzheimer's disease].

Gavrilova SI, Fedorova IaB, Kolykhalov IV, Odinak MM, Emelin AIu, Kashin AV, Selezneva ND, Kalyn IaB, Roshchina IF

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2008

PMID18833104 (opens in a new tab)PepBankPUB-18833104
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with amnestic mild cognitive impairment, the open comparative study reported that Cerebrolysin course therapy prevented cognitive deficit progression.

    In plain wordsIn patients with amnestic mild cognitive impairment, Cerebrolysin course therapy reportedly prevented cognitive decline compared with no Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseProgression of cognitive deficit
    Study

    n = 73

    Comparator
    Patients not receiving Cerebrolysin
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 2 years, courses repeated every 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Such therapy allows to prevent the progression of cognitive deficit and development of dementia of Alzheimer's type.
    2 context sentences
    Summary · context
    The effect of the 2-years course therapy with cerebrolysin suggested by the authors has been proven.
    Summary · context
    has been studied in the open comparative study of 73 patients divided into 2 groups, one of which included patients treated with cerebrolysin and another one those who did not receive this drug.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with amnestic mild cognitive impairment, the open comparative study reported that Cerebrolysin course therapy prevented Alzheimer-type dementia development.

    In plain wordsIn patients with amnestic mild cognitive impairment, Cerebrolysin course therapy reportedly prevented Alzheimer-type dementia compared with no Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseDevelopment of Alzheimer-type dementia
    Study

    n = 73

    Comparator
    Patients not receiving Cerebrolysin
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 2 years, courses repeated every 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Such therapy allows to prevent the progression of cognitive deficit and development of dementia of Alzheimer's type.
    2 context sentences
    Summary · context
    The effect of the 2-years course therapy with cerebrolysin suggested by the authors has been proven.
    Summary · context
    has been studied in the open comparative study of 73 patients divided into 2 groups, one of which included patients treated with cerebrolysin and another one those who did not receive this drug.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.